HomeCompareJCOM vs ABBV

JCOM vs ABBV: Dividend Comparison 2026

JCOM yields 7.01% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $70.5K in total portfolio value
10 years
JCOM
JCOM
● Live price
7.01%
Share price
$142.84
Annual div
$10.02
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.8K
Annual income
$1,095.19
Full JCOM calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JCOM vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJCOMABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JCOM + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JCOM pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JCOM
Annual income on $10K today (after 15% tax)
$596.26/yr
After 10yr DRIP, annual income (after tax)
$930.91/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,125.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JCOM + ABBV for your $10,000?

JCOM: 50%ABBV: 50%
100% ABBV50/50100% JCOM
Portfolio after 10yr
$67.1K
Annual income
$12,933.48/yr
Blended yield
19.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JCOM
No analyst data
Altman Z
3.3
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JCOM buys
0
ABBV buys
0
No recent congressional trades found for JCOM or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJCOMABBV
Forward yield7.01%3.06%
Annual dividend / share$10.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$31.8K$102.3K
Annual income after 10y$1,095.19$24,771.77
Total dividends collected$9.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JCOM vs ABBV ($10,000, DRIP)

YearJCOM PortfolioJCOM Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,401$701.48$11,550$430.00$149.00ABBV
2$12,947$747.47$13,472$627.96$525.00ABBV
3$14,647$793.27$15,906$926.08$1.3KABBV
4$16,511$838.70$19,071$1,382.55$2.6KABBV
5$18,550$883.58$23,302$2,095.81$4.8KABBV
6$20,776$927.77$29,150$3,237.93$8.4KABBV
7$23,202$971.14$37,536$5,121.41$14.3KABBV
8$25,839$1,013.56$50,079$8,338.38$24.2KABBV
9$28,703$1,054.94$69,753$14,065.80$41.0KABBV
10$31,807$1,095.19$102,337$24,771.77$70.5KABBV

JCOM vs ABBV: Complete Analysis 2026

JCOMStock

J2 Global, Inc., together with its subsidiaries, provides Internet services worldwide. The company operates through three segments: Fax and Martech; Voice, Backup, Security, and Consumer Privacy and Protection; and Digital Media. It offers cloud services, which includes online fax services under the eFax, sFax, MyFax, eFax Plus, eFax Pro, eFax Secure, eFax Corporate, and eFax Developer brands; on-demand voice, cloud phone, and unified communications services under the eVoice, Line2, and Onebox names; online backup and disaster recovery, sync storage, veeam services, and synchronization and sharing solutions under the KeepItSafe, LiveDrive, LiveVault, OffsiteDataSync, and SugarSync names; email security, web security, and endpoint protection services under the VIPRE and Excel Micro brands; email marketing and delivery services under the Campaigner and SMTP names; virtual private network services under the IPVanish and Encrypt.me; IP licensing services; and customer support services. The company also operates a portfolio of Web properties and applications, including IGN, Mashable, PC Mag, Humble Bundle, Speedtest, Offers, Black Friday, AskMen, MedPageToday, Everyday Health, What to Expect, and others that offer technology products, gaming and lifestyle products and services, news and commentary related products, speed testing for Internet and network connections, online deals and discounts for consumers, interactive tools and mobile applications, and tools and information for healthcare professionals, as well as professional networking tools, targeted emails, and white papers for IT professionals. It serves sole proprietors, small to medium-sized businesses and enterprises, and government organizations. The company was formerly known as j2 Global Communications, Inc. and changed its name to j2 Global, Inc. in December 2011. J2 Global, Inc. was founded in 1995 and is headquartered in Los Angeles, California.

Full JCOM Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JCOM vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JCOM vs SCHDJCOM vs JEPIJCOM vs OJCOM vs KOJCOM vs MAINJCOM vs JNJJCOM vs MRKJCOM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.